Cabozantinib plus nivolumab and ipilimumab improves response in low GDS mRCC while high GDS predicts worse survival

Enzalutamide plus radium-223 extends survival in bone metastatic prostate cancer

Circulating tumour DNA shows high accuracy for monitoring testicular cancer across all stages

Cabozantinib plus nivolumab and ipilimumab shows promising brain metastasis control in advanced kidney cancer

Belzutifan plus palbociclib shows modest activity with manageable safety in heavily pretreated kidney cancer

Circulating tumour DNA dynamics predict outcomes with pembrolizumab in advanced kidney cancer

HIF-2α inhibitor Cas shows durable responses and biomarker-linked benefit in metastatic kidney cancer

Pembrolizumab plus belzutifan improves disease-free survival in high-risk kidney cancer after surgery

Darolutamide improves progression-free survival across comorbidities in metastatic hormone-sensitive prostate cancer

Durvalumab plus tremelimumab temporarily reduces QoL in resected renal cell carcinoma patients

Induction ipilimumab plus nivolumab followed by chemoradiotherapy achieves high bladder preservation and survival in MIBC

Lutetium-177 PSMA-617 improves progression-free survival without worsening QoL in mHSPC